×

$8.3 billion biotech deal

5:00 PM ET Mon, 25 Aug 2014

Robyn Karnauskas, Deutsche Bank biotechnology analysis, discusses which companies could be the next takeover target in the biotech space following Roche's acquisition of InterMune.